News

Sabarish Ram Ayyappan, MD, discusses the mechanism of action of odronextamab and highlights the phase 2 ELM-2 trial which evaluated the agent in patients with relapsed/refractory diffuse large B-cell lymphoma.

The FDA completed an advice meeting with the manufacturer of olaptesed pegol in anticipation of the filing of an investigational new drug application in Q1 of 2024.

A phase 1a study of HF1K16 for the treatment of patients with solid tumors has been completed and deemed well-tolerated.

Combining a CDK9 inhibitor with venetoclax and prednisone led to encouraging responses in patients with lymphoid malignancies in the dose-escalation arm of a phase 1 clinical trial.

Pembrolizumab plus cabozantinib showed promising activity with an objective response rate of 65.8%, median progression-free survival of 10.45 months, and median overall survival of 30.81 months in metastatic renal cell carcinoma.

Rucaparib showed a significant improvement in progression-free survival compared with docetaxel in metastatic castration- resistant prostate cancer.

The FDA has approved the new drug application of a ready-to-dilute formulation of a treatment for breast and ovary adenocarcinoma.

With an investigational new drug application cleared by the FDA, a multi-center, open-label, modified dose-escalation, phase 1b trial of ACT-IOP-003 will begin in pancreatic cancer.

The supplemental biologics license application approval is based on findings from the phase 3 innovaTV 301 trial investigating tisotumab vedotin vs investigator’s choice of chemotherapy in cervical cancer.

Treatment with trastuzumab maintains its place as the backbone of therapy in the first-line setting for management of patients with HER2-positive metastatic breast cancer.

NUV-1511, a novel drug candidate for the treatment of solid tumors, has received clearance from the FDA for its investigational new drug application.

The FDA has issued a complete response letter to the biologics license application of zolbetuximab for patients with advanced, HER2-negative, claudin 18.2-positive gastric or gastoesophageal junction adenocarcinoma.

The landmark study, KEYNOTE-564, compared pembrolizumab vs placebo in patients with clear cell renal cell carcinoma who were at high risk for recurrence after nephrectomy.

Douglas Tremblay, MD, discusses the use and potential benefits and risks of cytoreduction for patients with essential thrombocytopenia and polycythemia vera.

Findings from the phase 3 ASC4FIRST trial showed that asciminib demonstrated encouraging major molecular response in patients with Philadelphia chromosome-positive chronic myeloid leukemia.

A Safe to Proceed letter from the FDA has been granted to the investigational new drug application of a phase 2 study evaluating ropidoxuridine plus radiotherapy in patients with newly diagnosed IDH-wildtype glioblastoma.

Haifa Kathrin Al-Ali, MD, discussed findings from the phase 1/2 CA011-023 study of BMS-986158 combined with ruxolitinib or fedratinib in myelofibrosis.

Iopofosine I-131 showed impressive results in a study for patients with advanced Waldenstrom's macroglobulinemia, achieving a major response rate of 61%.

The ECHELON-2 study compared brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone chemotherapy with the standard-of-care cyclophosphamide, doxorubicin, vincristine, and prednisone regimen for CD30- positive T-cell lymphoma.

Francis P. Worden, MD, discusses the efficacy findings from the phase 3 COSMIC-311 study of cabozantinib in thyroid cancer.

Findings from the MOMENTUM study evaluating momelotinib demonstrated symptom, spleen, and anemia benefits in myelofibrosis compared with danazol in previously treated patients with anemia and intermediate- or high-risk myelofibrosis.

Edward B. Garon, MD, MS, provides an overview of some of the available treatment options for patients with EGFR-mutated lung cancer.

Sarah B. Goldberg, MD, MPH, presented these findings to demonstrate the effective time to use immuno-oncology combination therapy during the 41st Annual Chemotherapy Foundation Symposium Innovative Cancer Therapy for Tomorrow.

In an interview with Targeted Oncology, Ann LaCasce, MD, MMSc, delved into the surge of innovations with personalized medicine, advanced technologies, and novel agents for the treatment of patients with lymphomas.

The phase 2 DisTinGuish study is evaluating the combination of DKN-01, tislelizumab, and chemotherapy for the first-line treatment of patients with advanced gastroesophageal adenocarcinoma.

Findings from a phase 3 trial of the Bria-IMT regimen showed a 71% intracranial objective response rate in patients with breast cancer and central nervous system metastases.

Rinatabart sesutecan is an antibody drug conjugate that has now received a fast track designation from the FDA for the treatment of FRα-expressing ovarian cancer.

In a presentation during the 41st Annual Chemotherapy Foundation Symposium Innovative Cancer Therapy for Tomorrow conference, Jessica Lin, MD, discussed the landscape of targeted therapies in driver mutations in non–small cell lung cancer.

Leticia Nogueira, PhD, MPH, discusses how healthcare professionals and patients can come together facing the threats of climate change on cancer care.

Following a patient death in the phase 2 IOV-LUN-202 trial, the FDA has issued a clinical hold.